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To determine whether the presence of periodontitis (PD) and Porphyromonas gingivalis
(Pg) in the subgingival biofilm associates with the development of rheumatoid arthritis (RA)
in treatment naïve preclinical stage of arthritis patients.
Methods
We conducted a prospective cohort study of 72 consecutive patients with arthralgia who
had never been treated with any anti-rheumatic drugs or glucocorticoids. Periodontal status
at baseline was assessed by dentists. PD was defined stringently by the maximal probing
depth≧4 mm, or by the classification by the 5th EuropeanWorkshop in Periodontology
(EWP) in 2005 using attachment loss. Up to eight plaque samples were obtained from each
patient and the presence of Pg was determined by Taqman PCR. The patients were fol-
lowed up for 2 years and introduction rate of methotrexate (MTX) treatment on the diagnosis
of RA was compared in patients with or without PD or Pg.
Results
Patients with PD (probing depth≧4mm) had higher arthritis activity (p = 0.02) and higher risk
for future introduction of MTX treatment on the diagnosis of RA during the follow up than pa-
tients without PD (Hazard ratio 2.68, p = 0.03). Arthritis activity and risk for MTX introduction
increased with the severity of PD assessed by EWP, although not statistically significant.
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On the other hand, presence of Pg was not associated with arthritis activity (p = 0.72) or the
risk for MTX introduction (p = 0.45).
Conclusion
In treatment naïve arthralgia patients, PD, but not the presence of Pg, associates with arthri-
tis activity and future requirement of MTX treatment on the diagnosis of RA.
Introduction
Recent studies have suggested a correlation between periodontitis (PD) and rheumatoid arthri-
tis (RA)[1]. Epidemiological studies have reported the increased prevalence of PD in RA pa-
tients[2] [3]. PD and RA share some underlying pathological processes such as involvement of
inflammatory cytokines and bone resorption[1]. In addition, recent studies suggested the spe-
cific role of a periodontal pathogen, Porphyromonas gingvalis (Pg) for anti-citrullinated pro-
tein/peptide antibody (ACPA) production for RA [4] [5]. To date, Pg is the only known
eubacteria expressing peptidylarginine deaminase that citrullinates human fibrinogen or α-
enolase in vitro [6] [7] and it is postulated that Pg infection might be a cause of ACPA produc-
tion and subsequent RA development [4] [5] [8]. However, this hypothesis has not been fully
determined in vivo yet.
Recent evidences suggested the importance of microbiome in the mucosal surface for the
development of autoimmune diseases[9]. For example, a single commensal bacteria, segmented
filamentous bacteria, was responsible for the development of inflammatory helper T cell subset
(Th17 cells) and for the development of autoimmune arthritis in mice[10]. Presence of clos-
tridia strains in the colon induces regulatory T cells in humans which is important for the
maintenance of immune tolerance[11]. Therefore, it is possible that an alteration in the micro-
biome in the gut or gummay tilt the balance of immune homeostasis and influence the autoim-
mune disease manifestation. Based on the above mentioned close epidemiological and
pathological relationship between PD and RA[1], it is interesting to determine whether the
presence of PD or Pg in subgingival biofilm drives the development of RA.
To study the true temporal relationship between PD or Pg and RA, a prospective study of
treatment naïve, preclinical stage of arthritis patients is necessary. Immunosuppressive treat-
ments for RA may alter PD status and periodontal biofilm of the patients. In addition, to deter-
mine the role of the periodontal pathogens in subgingival biofilm for the development of RA,
presence of periodontal pathogens should be directly determined by a DNA sequence-based
method[9]. DNA of subgingival biofilm have been analyzed in various diseases such as arthero-
sclerosis or coronary heart diseases which revealed the association between PD/Pg and system-
ic diseases[12] [13]. However, only a few studies have analyzed the periodontal biofilm in RA
patients[14] [15].
In this study, we conducted a prospective cohort study of treatment-naïve arthralgia patient
to confirm whether the presence of clinical PD or Pg in subgingival biofilm associates with ar-
thritis activity and future development of RA.
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We conducted a prospective cohort study at the Center for Rheumatic Diseases in conjunction
with the Department of Oral and Maxillofacial Surgery in Kyoto University Hospital. Inclusion
criteria were the patients aged at least 18 years old when they first visited the center fromMay
1st in 2011 to December 31st in 2012, who did not have definite diagnosis for arthralgia before
the referral to the hospital, and who have never been treated with any synthetic or biologic dis-
ease modifying anti-rheumatic drugs or glucocorticoids. Exclusion criteria were patients diag-
nosed as osteoarthritis without any signs or symptoms of inflammatory synovitis, those who
had less than ten teeth remaining, and those who have been treated with antibiotics within one
month before the visit. At the first visit to the Center for Rheumatic Diseases, all the patients
were referred to the Department of Oral and Maxillofacial Surgery and received full examina-
tion of the oral status by trained dentists. The diagnosis of PD was determined by dentists and
subgingival plaque samples were obtained and the amount of Pg DNA in biofilm was deter-
mined. Then, the study patients were prospectively followed up by rheumatologists for 2 years
and initiation of methotrexate (MTX) treatment on the diagnosis of RA was recorded. Rheu-
matologists and dentists evaluated each patient independently and were blinded from each
other for the patients’ dental or rheumatologic status. The study was designed in accordance
with the Helsinki declaration and was approved by the ethics committee of Kyoto University
Hospital. Written informed consent was obtained from all the patients.
Assessment of periodontal status and definition for the diagnosis of
periodontitis
The periodontal examination was conducted by trained dentists (TY, KA, YI). Calibration of
periodontal probing was performed prior to the study. The inter examiner kappa index was 0.7
to 0.9. Clinical data on PD included the number of present teeth, probing depth, attachment
loss, bleeding of probing, and plaque control record. Probing depth was measured for all teeth
at six sites per tooth (mesio-buccal, misio-lingal, disto-buccal, disto-lingal, mid-buccal and
mid-lingal) by UNC-15 probe (Hu-Friedy)[16]. Bleeding of probing was expressed as the per-
centage of bleeding sites over the total number of tooth surfaces. Oral hygiene was measured
using O’Leary’s plaque control record[17]. Presence of PD was defined stringently by the pres-
ence of any sites exhibiting probing depth≧4 mm [16] or based upon the classification by the
5th European Workshop in Periodontology (EWP) in 2005 using attachment loss (Moderate
PD; presence of proximal attachment loss of ≧3 mm in≧2 non-adjacent teeth. Severe PD;
presence of proximal attachment loss of≧5 mm in≧30% of teeth present) [18]. Lifestyle habits
that affect PD status such as smoking and tooth brushing were also recorded[19].
Definition for the presence of P. gingivalis in subgingival biofilm
To analyze the presence of Pg in subgingival biofilm independent of PD status, subgingival pla-
que samples were obtained from the mesio-buccal sites of two most posterior teeth in each
quadrant as available, irrespective of their periodontal states[12]. Up to eight (average 7.9) sub-
gingival plaque samples were collected for each patient. Teeth were gently dried with sterile
cotton swabs. After removing supragingival plaque by cotton pellets and air-drying, subgingi-
val plaque was collected with two sterile paper points inserted into the bottom of the periodon-
tal pocket or gingival crevice for 20 seconds[20]. Bacterial DNA was extracted by Nucleospin
tissue XS kit according to the manufacturer’s instructions. Bacterial DNA was not extracted in
one patient. Genomic DNA was amplified by specific Taqman primers and probes designed
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from the variable regions of 16s rRNA of eubacteria gene[21] and quantified by ABI PRISM
7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Presence of Pg in sub-
gingival biofilm was defined stringently as the detection of Pg genomic DNA in at least one site
out of eight plaque samples per patient. The bacterial load of Pg was determined by real time
PCR normalized with that of total eubacteria gene (Universal) [21], summed up for eight pla-










Assessment of arthritis status
Clinical and laboratory data on arthritis was obtained by rheumatologists (MH, MF, HI, TF)
and stored in the Kyoto University Rheumatoid Arthritis Management Alliance (KURAMA)
database [22]. Clinical data included age, sex, disease duration of joint symptoms, swollen joint
count, tender joint count, patient’s global assessment of disease activity, and physician’s global
assessment of disease activity. Arthritis activity was assessed by simplified disease activity
index (SDAI). Physical disability was assessed by modified health assessment questionnaire
(mHAQ). Serological data included CRP, ACPA (anti-CCP2 antibody enzyme-linked immu-
nosorbent assay), and rheumatoid factor (latex agglutination turbidimetry).
Definition of RA diagnosis
RA diagnosis at the first visit was based upon the American College of Rheumatology / Europe-
an League Against Rheumatism (ACR/EULAR) classification criteria for RA in 2010[23]. The
diagnosis of RA at the end of the follow up was based upon the primary rheumatologists’ diag-
nosis[24].
Endpoint
We set the endpoint of our study not by the fulfillment of the 2010 ACR/EULAR criteria but
by the introduction of MTX treatment on the diagnosis of RA by rheumatologists. MTX is the
anchor drug for the treatment of RA which is used for more than 80% of RA patient as the first
DMARDs[25]. Because early MTX treatment in probable RA patients prevents the patients
from developing into RA fulfilling the 2010 ACR/EULAR criteria[26], it is recommended to
consider the initiation of MTX treatment on the suspected diagnosis of RA if the patient has
chronic inflammatory synovitis and other differential diagnosis such as psoriatic arthritis were
excluded by professional rheumatologist[27].
Statistical Analyses
Continuous variables were expressed as mean ± SD and categorical variables were expressed as
percentages (numbers). The study patients were divided into two groups based on the presence
of PD (maximal probing depth ≧ 4 mm) or the presence of Pg in subgingival biofilm, and were
divided into 3 groups based upon severity of PD (EWP; none, moderate, and severe). The dif-
ference of continuous variables between 2 groups were analyzed by Students’ t-test and those
Periodontitis and Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0122121 April 7, 2015 4 / 13
among three groups were analyzed by Kruskal-Wallis test. The difference of categorical vari-
ables between the two groups were analyzed by Pearson’s qui-squared test and those among
three groups were analyzed by Kruskal-Wallis test. The effect the presence of PD (maximal
probing depth ≧4 mm or EWP; none, moderate, and severe) or Pg on arthritis activity (SDAI)
was analyzed by multivariate analysis of covariance (ANCOVA) adjusted for major confound-
ing factors associated with periodontitis such as age, sex, smoking status, and tooth brushing
habit[19]. The introduction rate of MTX treatment in each groups were analyzed by cumula-
tive hazard method. Association between the alteration of the diagnosis for joint symptoms
(RA!RA, non RA!RA, and non RA!non RA) and the presence of PD or Pg were analyzed
by Pearson’s qui squared test. P values less than 0.05 was considered statistically significant.




During the study period, 87 patients were referred to the Center for Rheumatic Diseases as sus-
pect of RA without prior use of any synthetic or biological disease modifying anti-rheumatic
drugs or glucocorticoids. Following the exclusion criteria, 14 osteoarthritis patients without
any signs or symptoms of inflammatory synovitis and one patient who had less than ten teeth
were excluded. No patients were treated with antibiotics within one month. In the end, 72 pa-
tients were defined as the study patients and followed up prospectively for 2 years. The baseline
characteristics of the study patients are shown in Table 1. Among the study patients, 68.1%
(49) of the patients had at least one sites probing depth≧4mm and diagnosed as having PD
(probing depth≧4mm). Based on the EWP classification using attachment loss, 9.7% was clas-
sified as non PD, 83.3%(60) as moderate PD, and 6.9%(5) as severe PD. After the determina-
tion of Pg genomic DNA by Taqman PCR, 59.2% (42) of the patients were defined as Pg
positive. By the examination by rheumatologists, 41.7% (30) of the patients fulfilled 2010 ACR/
EULAR criteria for RA at baseline (Table 1).
Arthritis activity
At baseline, patients with PD (probing depth≧4mm) had higher arthritis activity than patients
without PD (SDAI 14.2±10.4 vs 8.6±7.1, p = 0.02) (Table 2). Arthritis activity such as SDAI,
SJC, TJC, and CRP also increased with PD (EWP), although the difference did not reach the
statistical cut-off of the statistics (Table 2). Both the diagnosis of PD (probing depth≧4mm)
and PD(EWP) well correlated with parameters of PD such as bleeding on probing (p = 0.01 for
PD (probing depth≧4mm) and p = 0.002 for PD (EWP)) (Table 2). RA diagnosis by 2010
ACR/EULAR criteria and ACPA/RF status were not different in the study groups.
On the other hand, when the patients were divided into two groups based on the presence
or absence of Pg in biofilm, arthritis activity was not different in the two groups (12.9±10.7 vs
12.0±8.6 p = 0.72) (Table 2). RA diagnosis and ACPA/RF status were also not different in the
two groups. Age was the only factor that was significantly associated with Pg status (57.0±13.3
vs 48.6±15.9, p = 0.02) (Table 2). Presence of Pg slightly correlated with parameters of PD such
as probing depth (p = 0.08), attachment loss (p = 0.13), and oral hygiene status (p = 0.08), al-
though they did not reach the significance cut off of the statistics (Table 2).
The presence of PD (maximal probing depth≧4 mm) remained significantly associated
with arthritis activity (SDAI) by multivariate analysis (p = 0.02, effect size 0.08–0.09), even
after adjustment for major confounding factors associated with PD status such as age, sex,
smoking, tooth brushing habit, and the presence of Pg in biofilm (Table 3). In contrast, the
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presence of PD defined by EWP was not associated with SDAI by multivariate analysis
(Table 4).
Methotrexate treatment introduction
The patients were followed up and the introduction rate of MTX treatment during the follow
up period were compared based upon the presence or absence of PD (probing depth≧4mm),
severity of PD (EWP), or the presence or absence of Pg at baseline (Fig 1). When the patients
were divided into two groups by the presence or absence of PD (probing depth≧4mm), pa-
tients with PD (probing depth≧4 mm) were more frequently initiated with MTX treatment
than patients without PD (Hazard ratio 2.68 (95% Confidence Interval (CI), 1.11–6.50),
p = 0.03) (Fig 1A). When the patients were divided into three groups based on EWP, severe PD
(EWP) and moderate PD (EWP) patients had increased risk for the future introduction of
MTX treatment compared with non PD patients (Sever vs non PD; Hazard ratio 7.26, (95% CI,
Table 1. Baseline characteristics of the study patients.
N = 72
Age, years 53.4 ± 14.9
Female, % 90.3% (65)
Body mass index, kg/m2 21.9 ± 3.6
Smoking (current or ever), % 29.2% (21)
Number of tooth brushing /day 2.2 ± 0.7
Number of present teeth 24.8 ± 4.1
Probing depth (maximal), mm 4.1 ± 1.2
Attachment loss (maximal), mm 5.1 ± 1.9
Bleeding of probing, % 6.6 ± 7.7
Plaque control record, % 27.5 ± 17.0
Total bacterial load, arbitrary unit 1180 ± 480
P. gingivalis positive, % 59.2% (42)
P. gingivalis, arbitrary unit 0.2 ± 0.3
PD (probing depth≧4mm) 68.1% (49)
PD (EWP) None 9.7% (7)
PD (EWP) Moderate 83.3% (60)
PD (EWP) Severe 6.9% (5)
Duration of joint symptoms, months 26.8 ± 60.9
Swollen joint count 2.4 ± 3.4
Tender joint count 2.7 ± 3.0
CRP, mg/dl 0.90 ± 1.58
Patient’s global assessment, mm 20.7 ± 23.5
Physician’s global assessment, mm 46.7 ± 28.2
SDAI 12.5 ± 9.8
mHAQ 0.3 ± 0.5
Anti-CCP antibody positive, % 44.9% (31)
Rheumatoid factor positive, % 47.8% (33)
RA diagnosis at baseline, % 41.7% (30)
Continuous variables were expressed as mean ± SD. Categorical variables were expressed as %
(number). EWP: periodontitis classification criteria of the 5th European Workshop in Periodontology in
2005, SDAI: simplified disease activity index; mHAQ: modified health assessment questionnaire
doi:10.1371/journal.pone.0122121.t001
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Table 2. Characteristics of the patients divided by the clinical diagnosis of periodontitis or the presence of Porphyromonas gingivalis in subgingi-
val biofilm.
PD (probing depth≧4mm) PD (EWP) P.gingivalis
Negative Positive None Moderate Severe Negative Positive
N N = 23 N = 49 P N = 7 N = 60 N = 5 P N = 29 N = 42 P
Age, years 52.2 ± 17.0 53.9 ± 14.0 0.66 52.3 ± 19.4 53.0 ± 14.4 58.8 ± 10.2 0.73 48.6 ± 15.9 57.0 ± 13.3 0.02*
Female, % 95.7% (22) 87.8% (43) 0.42 100% (7) 93.3% (56) 40% (2) 0.0004* 96.6% (28) 85.7% (36) 0.23
Body mass index, kg/m2 21.2 ± 3.6 22.2 ± 3.5 0.25 21.6 ± 2.7 22.0 ± 3.7 21.6 ± 2.4 0.92 21.7 ± 4.0 22.1 ± 3.3 0.63
Smoking (current or
ever), %
21.7% (5) 32.7% (16) 0.41 42.9% (3) 25.0 (%)
15)
60.0% (3) 0.18 31% (9) 28.6% (12) 1
Number of tooth brushing
/day
2.5 ± 0.5 2.0 ± 0.7 0.003* 2.6 ± 0.5 2.2 ± 0.7 1.8 ± 0.7 0.81 2.2 ± 0.6 2.1±0.8 0.57
Number of present teeth 25.6 ± 4.0 24.4 ± 4.1 0.27 25.0 ± 4.3 24.8 ± 4.0 23.9 ± 3.9 0.81 25.3 ± 4.5 24.6 ± 3.6 0.51
Probing depth (maximal),
mm
2.9 ± 0.5 4.7 ± 1.0 N.A. 2.9 ± 0.3 4.1 ± 1.1 6.0 ± 0.6 0.001* 3.8 ± 1.0 4.3 ± 1.3 0.08
Attachment loss
(maximal), mm
4.0 ± 1.2 5.6 ± 2.0 0.0003* 3.4 ± 1.0 5.0 ± 1.5 8.6 ± 2.6 0.0003* 4.7 ± 1.5 5.4 ± 2.1 0.13
Bleeding of probing, % 3.3 ± 5.1 8.2 ± 8.3 0.01* 0.7 ± 0.8 6.4 ± 6.9 16.8 ± 11.2 0.002* 5.3 ± 5.9 7.6 ± 8.8 0.24
Plaque control record, % 24.4 ± 15.9 28.9 ± 17.5 0.3 24.1 ± 15.5 28.0 ± 17.6 26.0 ± 6.6 0.93 31.6 ± 19.9 24.5 ± 14.5 0.08
Total bacterial load,
arbitrary unit
1050 ± 470 1240 ± 471 0.04* 980 ± 230 1180 ± 500 1390 ± 400 0.25 1010 ± 450 1290 ± 460 0.005*
P. gingivalis positive, % 52.2% (12) 62.5% (30) 0.45 57.1% (4) 55.9% (33) 100% (5) 0.16 N.D. N.D. N.D.
P. gingivalis, arbitrary
unit
0.2 ± 0.3 0.3 ± 0.3 0.28 0.2 ± 0.3 0.2 ± 0.3 0.5 ± 0.4 0.09 0.0 ± 0.0 0.4±0.3 N.A.
PD (probing
depth≧4mm), %
N.D. N.D. N.D. 0% (0) 73.3% (44) 100% (5) 0.0001 62.1% (18) 71.4% (30) 0.45
PD (EWP) None, % 30.4% (7) 0.0% (0) N.A. N.D. N.D. N.D. N.D. 10.3% (3) 9.5% (4) N.A.
PD (EWP) Moderate, % 69.6%(16) 89.8% (44) N.A. N.D. N.D. N.D. N.D. 89.7% (26) 78.6% (33) N.A.
PD (EWP) Severe, % 0.0% (0) 10.2% (5) N.A. N.D. N.D. N.D. N.D. 0.0% (0) 11.9% (5) N.A.
Duration of joint
symptoms, months
11.0 ± 17.0 34.3 ± 71.9 0.13 13.1 ± 26.9 30.4 ± 65.0 2.8 ± 1.3 0.16 29.6 ± 69.5 25.5 ± 55.7 0.79
Swollen joint count 1.3 ± 2.2 2.9 ± 3.8 0.07 1.0 ± 1.8 2.4 ± 3.4 4.2 ± 4.3 0.29 1.9 ± 2.5 2.7 ± 3.9 0.31
Tender joint count 2.1 ± 2.3 3.0 ± 3.3 0.27 3.1 ± 3.0 2.4 ± 2.5 5.6 ± 5.4 0.46 2.7 ± 2.3 2.8 ± 3.5 0.86
CRP, mg/dl 0.8 ± 1.5 0.9 ± 1.6 0.81 0.7 ± 1.4 0.9 ± 1.6 1.0 ± 1.1 0.67 0.9 ± 1.8 0.9 ± 1.4 0.86
Patient's global
assessment,mm
36.5 ± 27.7 51.3 ± 27.5 0.04* 40.6 ± 28.1 46.1 ± 27.9 62.4 ± 23.3 0.26 43.2 ± 29.1 49 ± 28.1 0.4
Physician's global
assessment,mm
11.5 ± 12.5 24.8 ± 26.1 0.03* 12.9 ± 14.8 20.0 ± 22.3 39.4 ± 32.9 0.36 21.3 ± 23.3 20.8 ± 24 0.93
SDAI 8.6 ± 7.1 14.2 ± 10.4 0.02* 9.5 ± 7.8 12.2 ± 9.4 20.0 ± 11.8 0.33 12.0 ± 8.6 12.9 ± 10.7 0.72
mHAQ 0.3 ± 0.5 0.4 ± 0.4 0.44 0.1 ± 0.2 0.4 ± 0.5 0.4 ± 0.4 0.53 0.3 ± 0.5 0.4 ± 0.4 0.41
anti-CCP antibody
positive, %
38.1% (8) 47.9% (23) 0.6 50% (3) 43.1% (25) 60.0% (3) 0.74 55.2% (16) 38.5% (15) 0.22
Rheumatoid factor
positive, %
47.6% (10) 47.9% (23) 1 50% (3) 46.6% (27) 60.0% (3) 0.84 58.6% (17) 41.0% (16) 0.22
RA diagnosis at
baseline, %
43.5% (10) 40.8% (20) 1 42.9% (3) 49.0% (24) 60.0% (3) 0.68 44.8% (13) 40.5% (17) 0.81
Continuous variables were expressed as mean ± SD. The difference of continuous variables between two groups were analyzed by students’ t-test and
those among three groups were analyzed by Kruskal-Wallis test. Categorical variables were expressed as percentages (numbers). The difference of
categorical variables between two groups was analyzed by Pearson’s qui-squared test and those among three groups were analyzed by Kruskal-Wallis
test. EWP: periodontitis classification criteria of the 5th European Workshop in Periodontology in 2005; SDAI: simplified disease activity index; mHAQ:
modified health assessment questionnaire; N.D.: not determined; N.A.: not assessed
*: p<0.05 Pg was not analyzed in one patient because DNA of subgingival plaque sample was not successfully extracted.
doi:10.1371/journal.pone.0122121.t002
Periodontitis and Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0122121 April 7, 2015 7 / 13
0.75–69.9), p = 0.09, Moderate vs non PD; Hazard ratio 4.42 (95% CI, 0.60–32.4), p = 0.15), al-
though the difference did not reach the significance cut-off of the statistics (Fig 1B).
On the other hand, when the patients were divided into two groups based upon the presence
or absence of Pg in subgingival biofilm, hazard ratio for the introduction of MTX treatment
was not different in patients with or without Pg in subgingival biofilm (Pg positive vs Pg nega-
tive, hazard ratio 0.77 (95% CI, 0.39–1.53), p = 0.45) (Fig 1C).
Relationship between MTX treatment introduction and the alteration of RA diagnosis from
baseline to endpoint (RA!RA, non RA!RA, and non RA!non RA) were studied (Table 5).
Thirty patients were initially diagnosed as RA by 2010 ACR/EULAR criteria at baseline and
also diagnosed as RA by rheumatologists at endpoint (RA!RA). Thirteen patients who did
not fulfill 2010 ACR/EULAR criteria at baseline were additionally diagnosed as RA by rheuma-
tologists during the follow up period (non-RA!RA). The remaining 29 patients were classified
Table 3. Multivariate analysis of covariance for factors associated simplified disease activity index of rheumatoid arthritis.
For SDAI Model 1 Mode 2 Model 3
P ES P ES P ES
Age 0.16 0.03 0.15 0.03 0.16 0.03
Women 0.01* 0.10 0.01* 0.09 0.01* 0.11
Number of tooth brushing /day 0.19 0.03 0.62 0.00 0.21 0.03
Current smoker 0.82 0.00 0.66 0.00 0.87 0.00
PD (probing depth≧4mm) 0.02* 0.08 N.D. N.D. 0.02* 0.09
P. gingivalis positive N.D. N.D. 0.68 0.00 0.65 0.00
Multivariate analysis of covariance was used to analyze the effect size of the clinical diagnosis of periodontitis based upon maximal probing depth≧4 mm
and the presence of P. gingivalis for disease activity of rheumatoid arthritis after adjusting for age, sex, smoking status, frequency of tooth brushing per a




Table 4. Multivariate analysis of covariance for factors associated simplified disease activity index of
rheumatoid arthritis.
For SDAI Model 4 Model 5
P ES P ES
Age 0.14 0.03 0.15 0.04
Women 0.04* 0.06 0.05* 0.06
Number of tooth brushing /day 0.52 0.01 0.63 0.00
Current smoker 0.56 0.01 0.49 0.01
PD (probing depth ≧ 4mm) 0.69 0.01 0.65 0.01
P. gingivalis positive N.D. N.D. 0.50 0.01
Multivariate analysis of covariance was used to analyze the effect size of the clinical diagnosis of
periodontitis based upon the 5th European Workshop in Periodontology (EWP) in 2005 (0: no periodontitis,
1: moderate periodontitis, 2: severe periodontitis) and the presence of P. gingivalis for disease activity of
rheumatoid arthritis after adjusting for age, sex, smoking status, frequency of tooth brushing per a day.
Disease activity of rheumatoid arthritis was evaluated by simplified disease activity index. SDAI; simplified
disease activity index, P; P value, ES; Effect size
*; p<0.05
doi:10.1371/journal.pone.0122121.t004
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as non-RA throughout the period (non-RA!non-RA), which included Sjögren syndrome (3),
pseudogout (2), polymyalgia rheumatica (1), tenosynovitis (1), and 30.6% (22) patients re-
mained undifferentiated. MTX treatment was introduced in 80.0% of the RA!RA and 76.9%
of the non-RA!RA patients but none in the non-RA!non-RA patients. In this study, no pa-
tients were initiated with MTX treatment due to other differential diagnosis than RA, such as
psoriatic arthritis. Notably, both the presence of PD (probing depth≧4mm) and Pg was more
enriched in the disease progression group (non-RA!RA) compared with non-RA (non-
RA!non RA) patients (92.3% vs 55.2%, p = 0.04 for PD (probing depth≧4mm) and 61.5% vs
40.0%, p = 0.04 for Pg) (Table 5).
Fig 1. Hazard ratio for methotrexate treatment introduction during the follow up period. The patients were divided into two groups based upon the
diagnosis of PD (maximal probing depth≧ 4 mm) (a), three groups based upon the severity of PD (EWP) (b), or two groups based upon the presence of P.
gingivalis in subgingival biofilm (c). MTX treatment introduction in each groups were compared by cumulative hazard method. X axis indicates days for MTX
treatment introduction after the first visit. Y axis indicates the cumulative hazard ratio for MTX introduction. Hazard ratio of positive PD (probing depth≧4mm)
vs negative PD was 2.68 (95% CI, 1.11–6.50), p = 0.03. Hazard ratio of severe PD (EWP) vs non PD (EWP) was 7.26 (95% CI, 0.75–69.9), p = 0.09, and
hazard ratio of moderate PD vs non PD was 4.42 (95% CI, 0.60–32.4), p = 0.15. Hazard ratio of positive Pg vs negative Pg was 0.77 (95% CI, 0.39–1.53),
p = 0.45.
doi:10.1371/journal.pone.0122121.g001
Table 5. Diagnosis for joint symptoms at baseline and endpoint.
Baseline!Endpoint MTX PD at baseline Pg at baseline
RA!RA (30) 80.0% (24) 70.0% (21) 43.3% (13)
non RA!RA (13) 76.9% (10) 92.3% (12) 61.5% (8)
non RA!non RA (29) 0.0% (0) 55.2% (16) 40.0% (8)
Diagnosis at baseline is based upon the American College of Rheumatology / European League against Rheumatism (ACR/EULAR) classification criteria
for RA in 2010. Diagnosis of RA at endpoint is based upon primary rheumatologists’ diagnosis. Diagnosis at endpoint is based upon the primary
rheumatologists’ diagnosis. The diagnosises in non RA!non RA group was Sjogren syndrome (3), Pseudogout (2), Polymyalgia rheumatic (1),
Tenosynovitis (1), and Undifferentiated arthritis (22). MTX; methotrexate treatment introduction, PD; diagnosis of periodontitis (maximal probing
depth≧4mm), Pg; presence of Porphyromolas gingivalis in subgingival biofilm. Categorical variables were expressed as percentages (numbers) and were
analyzed by Pearson’s qui squared test. P values for the different PD status groups at baseline are 0.36 (RA!RA vs non RA!non RA), 0.23 (RA!RA vs
non RA!RA), 0.04 (non RA!RA vs non RA!non RA), respectively. P values for different Pg status groups at baseline are 0.37 (RA!RA vs non
RA!non RA), 0.44 (RA!RA vs non RA!RA), 0.04 (non RA!RA vs non RA!non RA), respectively.
doi:10.1371/journal.pone.0122121.t005
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Discussion
In this study, we showed that in patients with arthralgia who have never been treated with any
anti-rheumatic drugs or glucocorticoids, patients with PD had higher arthritis activity and in-
creased risk for future introduction of MTX treatment on the diagnosis of RA than patients
without PD. Because this study was performed prospectively on a unique cohort of treatment
naïve arthralgia patients, our results suggest that the association between PD and RA is not a
mere coincidence, but may have a causal relationship. This study complements and extends
the previous studies corroborating the association between PD and RA[1] [14] [28].
In our study, presence of PD (probing depth≧4mm) was associated with arthritis severity
and future introduction of MTX treatment. In addition, the severity of PD assessed by EWP
classification using attachment loss also correlated with arthritis activity and introduction of
MTX treatment, although the difference did not reach the significance cut off the statistics. PD
was more enriched in preclinical stage of arthritis (non RA!RA) patients who did not meet
the 2010 ACR/EULAR criteria at baseline but later diagnosed as RA by rheumatologists. These
results suggest that PD may promote RA development by increasing the joint inflammation.
Because DNA of periodontal pathogens are often detected in synovial tissue of RA or athero-
sclerotic plaque of coronary heart diseases [29] [13], it is possible that periodontal pathogens
released from periodontal sites may circulate in the body, reach the synovial tissue, and pro-
mote joint inflammation. Activation of innate immunity by periodontal pathogen-derived
products provokes chronic joint inflammation in predisposed individuals as is shown by ani-
mal models of RA [30] [31].
In contrast with positive correlation between PD and arthritis activity, Pg in subgingival bio-
film was not associated with arthritis activity or introduction of MTX treatment. This may be
due to several reasons. First, Pg is not the only bacterium that causes PD. PD is a polymicrobial
infection caused by a number of pathogens including Pg, Treponema denticola, and Tannner-
ella forsythia [32] [20]. It is possible that not a single bacterium, but the combination of several
periodontal bacteria may be more closely correlated with PD and arthritis activity. It is also
possible that not Pg as a whole but some specific genotype of Pg might have a particular viru-
lent factor [33] and might be associated with RA development. Second, not the mere presence
of Pg in biofilm but the presence of inflammation in the context of PD may be important for
promoting RA development. Indeed, PD and Pg were enriched in the disease progression
group of arthritis (non RA!RA) compared with non RA patients (non RA!non RA). Third,
because age was the only factor that was significantly associated with Pg and Pg was detected
even in a half of the patients without PD, similar to previous reports (20), the presence of Pg
may not only reflect PD status but also represent the age related alteration of
subgingival biofilm.
In this study, we did not observe the positive correlation between Pg and ACPA status. The
result is not surprising assuming the small sample size of our study population. In addition, the
correlation between Pg and ACPA status may vary depending upon the methods to evaluate
Pg infection [14] [15] [34] [35]. In our study, we directly examined bacterial DNA by a PCR
based method to evaluate the current bacterial burden for the subsequent development of RA
[14] [15] [21], while some studies analyzed anti-Pg antibodies[34] [35]. Furthermore, the cor-
relation between Pg and ACPA or RA may be influenced by the genetic background of the pa-
tients such as HLA-DRB1 shared-epitope [34] [36]. The difference in the genetic backgrounds
of our Japanese patients and other ethnic groups may partly explain the different results [37]
[38].
Our study has several limitations. First, due to our strict inclusion/exclusion criteria, our
study population was small and selection bias may exist. Because patients with high arthritis
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activity and positive ACPA were easily diagnosed as RA and initiated with anti-rheumatic
drugs before the referral to our department, those patients were not included in our study.
Therefore, our study patients were enriched with ACPA negative (ACPA positivity 44.9%) and
relatively mild arthritis patients (average SDAI = 12.5). In addition, we did not find any associ-
ation between presence of PD defined by the classification of EWP and arthritis severity or in-
troduction of MTX treatment, possibly due to the small sample size. Future studies should be
performed in larger scale and in community-hospital based setup to fully determine the role of
PD or Pg for RA development. Second, because we defined MTX treatment introduction as the
final endpoint, we cannot exclude the possibility that MTX treated patients might include
other arthritis patients than RA, although the patients were evaluated by professional rheuma-
tologists [24]. However, as described in the methods section, it was not warranted in our de-
partment to wait for the patients to develop into established RA fulfilling the 2010 ACR/
EULAR criteria, despite the fact that early MTX treatment can prevent their progression to RA
[26].
Despite these limitations, this study is unique in that we conducted a cohort study of treat-
ment naïve arthralgia patients through the parallel evaluations by professional dentists and
professional rheumatologists to minimize the error introduced by self-reported PD or antibody
responses [2] [3] [35]. To assess the subgingival biofilm independent of the periodontal status,
we obtained 8 plaque samples from predetermined tooth sites in each patient[12] and the pres-
ence of Pg was analyzed by a highly specific PCR method[21]. We have shown that there is dis-
cordance between clinical PD and presence of Pg, and RA development is more associated with
clinical state of PD than the presence of Pg.
In conclusion, we have shown that PD, but not the presence of Pg in subgingival biofilm, is
significantly associated with arthritis activity and the future requirement of MTX treatment on
the diagnosis of RA in treatment naïve arthralgia patients. It will help in designing a strategy to
prevent RA development by controlling PD.
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